Goldman Sachs Maintains Neutral on Biogen, Raises Price Target to $436
Goldman Sachs analyst Terence Flynn maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $246 to $436.
Truist Securities Maintains Buy on Biogen, Raises Price Target to $647
Truist Securities analyst Robyn Karnauskas maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $458 to $647.
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves.
The Latest Barron’s Picks And Pans: DocuSign, UPS, Taiwan Semiconductor And More
The cover story in this weekend's Barron's examines how teenage traders are shaking up the market.
Other featured articles discuss which drugmakers benefit from a new market, why it is time to buy momentum stocks and how to safely hunt for yield.
Benzinga’s Bulls And Bears Of The Week: Apple, Amazon, Biogen, Bitcoin, Tesla And More
Benzinga has examined the prospects for many investor favorite stocks over the past week.
The past week's bullish calls included the e-commerce leader, a top biotech and the airlines.
Nvidia And Dollar Tree Lead The Nasdaq In A Mixed Day For The Markets
U.S. indices had another mixed day of trading following worse-than-expected U.S. jobless figures and inflation data released Thursday.
Thinking About Buying Stock Or Options In Tilray, Ocugen, Biogen Or Snowflake?
One of the most common questions traders have about stocks is “Why Is It Moving?”
That’s why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro. WIIMs are a one-sentence description as to why that stock is moving.
Benzinga Pro’s Top 5 Stocks To Watch For Friday, Jun. 11, 2021: BIIB, TTWO, KR, MEDS, ARMK
Today's 5 Stock Ideas
Biogen (BIIB) - Shares were upgraded to Outperform by a Bernstein analyst. The analyst set a $500 price target on Biogen shares. The new price target represented potential upside
Bernstein Upgrades Biogen to Outperform, Announces $500 Price Target
Bernstein analyst Aaron Gal upgrades Biogen (NASDAQ:BIIB) from Market Perform to Outperform and announces $500 price target.